Alzamend Neuro Stock Performance
| ALZN Stock | USD 1.26 0.03 2.33% |
The firm shows a Beta (market volatility) of -0.29, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Alzamend Neuro are expected to decrease at a much lower rate. During the bear market, Alzamend Neuro is likely to outperform the market. At this point, Alzamend Neuro has a negative expected return of -0.92%. Please make sure to confirm Alzamend Neuro's value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and price action indicator , to decide if Alzamend Neuro performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Alzamend Neuro has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
| Begin Period Cash Flow | 5.1 M |
Alzamend |
Alzamend Neuro Relative Risk vs. Return Landscape
If you would invest 235.00 in Alzamend Neuro on August 30, 2024 and sell it today you would lose (109.00) from holding Alzamend Neuro or give up 46.38% of portfolio value over 90 days. Alzamend Neuro is currently does not generate positive expected returns and assumes 3.6505% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Alzamend, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Alzamend Neuro Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Alzamend Neuro's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Alzamend Neuro, and traders can use it to determine the average amount a Alzamend Neuro's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2513
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALZN |
Estimated Market Risk
| 3.65 actual daily | 32 68% of assets are more volatile |
Expected Return
| -0.92 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.25 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Alzamend Neuro is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Alzamend Neuro by adding Alzamend Neuro to a well-diversified portfolio.
Alzamend Neuro Fundamentals Growth
Alzamend Stock prices reflect investors' perceptions of the future prospects and financial health of Alzamend Neuro, and Alzamend Neuro fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Alzamend Stock performance.
| Return On Equity | -44.08 | ||||
| Return On Asset | -2.14 | ||||
| Current Valuation | 5.68 M | ||||
| Shares Outstanding | 4.48 M | ||||
| Price To Book | 7.23 X | ||||
| EBITDA | (9.89 M) | ||||
| Cash And Equivalents | 11.53 M | ||||
| Cash Per Share | 0.12 X | ||||
| Total Debt | 300.71 K | ||||
| Book Value Per Share | (1.41) X | ||||
| Cash Flow From Operations | (8.27 M) | ||||
| Earnings Per Share | (142.87) X | ||||
| Total Asset | 631.59 K | ||||
| Retained Earnings | (54.02 M) | ||||
About Alzamend Neuro Performance
By examining Alzamend Neuro's fundamental ratios, stakeholders can obtain critical insights into Alzamend Neuro's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Alzamend Neuro is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia. Alzamend Neuro operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.Things to note about Alzamend Neuro performance evaluation
Checking the ongoing alerts about Alzamend Neuro for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Alzamend Neuro help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Alzamend Neuro generated a negative expected return over the last 90 days | |
| Alzamend Neuro may become a speculative penny stock | |
| Alzamend Neuro has high historical volatility and very poor performance | |
| Alzamend Neuro has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (9.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Alzamend Neuro currently holds about 11.53 M in cash with (8.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12. | |
| Alzamend Neuro has a poor financial position based on the latest SEC disclosures |
- Analyzing Alzamend Neuro's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Alzamend Neuro's stock is overvalued or undervalued compared to its peers.
- Examining Alzamend Neuro's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Alzamend Neuro's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Alzamend Neuro's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Alzamend Neuro's stock. These opinions can provide insight into Alzamend Neuro's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.